Peroxisome proliferator-activated receptor activity is involved in the osteoblastic differentiation regulated by bone morphogenetic proteins and tumor necrosis factor-α

Molecular and Cellular Endocrinology

Volumn 348, Issue 1, 2012, Pages 224-232

  Takano, Mariko ^a   Otsuka, Fumio ^a   Matsumoto, Yoshinori ^a   Inagaki, Kenichi ^a   Takeda, Masaya ^a   Nakamura, Eri ^a   Tsukamoto, Naoko ^a   Miyoshi, Tomoko ^a   Sada, Ken ei ^a   Makino, Hirofumi ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

Bone morphogenetic protein (BMP); Osteoblast; Peroxisome proliferator activated receptor (PPAR); Tumor necrosis factor (TNF )

Indexed keywords

ALKALINE PHOSPHATASE; BONE MORPHOGENETIC PROTEIN; BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN 4; BONE MORPHOGENETIC PROTEIN RECEPTOR 2; COLLAGEN TYPE 1; FENOFIBRIC ACID; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OSTEOCALCIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ANTAGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; SMAD1 PROTEIN; SMAD5 PROTEIN; SMAD6 PROTEIN; SMAD7 PROTEIN; SMAD8 PROTEIN; STAT PROTEIN; TRANSCRIPTION FACTOR RUNX2; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR;

ANIMAL CELL; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; MOUSE; NONHUMAN; OSTEOBLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION;

ALKALINE PHOSPHATASE; ANIMALS; ANTIGENS, DIFFERENTIATION; BONE MORPHOGENETIC PROTEINS; CELL DIFFERENTIATION; CELL LINE, TUMOR; COLLAGEN TYPE I; CORE BINDING FACTOR ALPHA 1 SUBUNIT; GENE EXPRESSION; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; OSTEOBLASTS; OSTEOCALCIN; OXAZOLES; PPAR ALPHA; PPAR GAMMA; RECEPTORS, TUMOR NECROSIS FACTOR; SIGNAL TRANSDUCTION; SMAD PROTEINS; TUMOR NECROSIS FACTOR-ALPHA; TYROSINE;

EID: 80755140548     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2011.08.027     Document Type: Article

References (35)

1. Akune T., Ohba S., Kamekura S., Yamaguchi M., Chung U.I., Kubota N., Terauchi Y., Harada Y., Azuma Y., Nakamura K., Kadowaki T., Kawaguchi H. PPARgamma insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. J. Clin. Invest. 2004, 113:846-855.
2. Celeste A.J., Iannazzi J.A., Taylor R.C., Hewick R.M., Rosen V., Wang E.A., Wozney J.M. Identification of transforming growth factor beta family members present in bone-inductive protein purified from bovine bone. Proc. Natl. Acad. Sci. USA 1990, 87:9843-9847.
3. Chan B.Y., Gartland A., Wilson P.J., Buckley K.A., Dillon J.P., Fraser W.D., Gallagher J.A. PPAR agonists modulate human osteoclast formation and activity in vitro. Bone 2007, 40:149-159.
4. Desvergne B., Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr. Rev. 1999, 20:649-688.
5. Ebisawa T., Tada K., Kitajima I., Tojo K., Sampath T.K., Kawabata M., Miyazono K., Imamura T. Characterization of bone morphogenetic protein-6 signaling pathways in osteoblast differentiation. J. Cell Sci. 1999, 112:3519-3527.
6. Feldmann M., Maini R.N. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?. Annu. Rev. Immunol. 2001, 19:163-196.
7. Gimble J.M., Robinson C.E., Wu X., Kelly K.A., Rodriguez B.R., Kliewer S.A., Lehmann J.M., Morris D.C. Peroxisome proliferator-activated receptor-gamma activation by thiazolidinediones induces adipogenesis in bone marrow stromal cells. Mol. Pharmacol. 1996, 50:1087-1094.
8. Grell M., Zimmermann G., Hulser D., Pfizenmaier K., Scheurich P. TNF receptors TR60 and TR80 can mediate apoptosis via induction of distinct signal pathways. J. Immunol. 1994, 153:1963-1972.
9. Grey A. Skeletal consequences of thiazolidinedione therapy. Osteoporos. Int. 2008, 19:129-137.
10. Grey A., Bolland M., Gamble G., Wattie D., Horne A., Davidson J., Reid I.R. The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. J. Clin. Endocrinol. Metab. 2007, 92:1305-1310.
11. Hughes F.J., Collyer J., Stanfield M., Goodman S.A. The effects of bone morphogenetic protein-2, -4, and -6 on differentiation of rat osteoblast cells in vitro. Endocrinology 1995, 136:2671-2677.
12. Jackson S.M., Demer L.L. Peroxisome proliferator-activated receptor activators modulate the osteoblastic maturation of MC3T3-E1 preosteoblasts. FEBS Lett. 2000, 471:119-124.
13. Jeon M.J., Kim J.A., Kwon S.H., Kim S.W., Park K.S., Park S.W., Kim S.Y., Shin C.S. Activation of peroxisome proliferator-activated receptor-gamma inhibits the Runx2-mediated transcription of osteocalcin in osteoblasts. J. Biol. Chem. 2003, 278:23270-23277.
14. Johnson T.E., Vogel R., Rutledge S.J., Rodan G., Schmidt A. Thiazolidinedione effects on glucocorticoid receptor-mediated gene transcription and differentiation in osteoblastic cells. Endocrinology 1999, 140:3245-3254.
15. Kang Q., Song W.X., Luo Q., Tang N., Luo J., Luo X., Chen J., Bi Y., He B.C., Park J.K., Jiang W., Tang Y., Huang J., Su Y., Zhu G.H., He Y., Yin H., Hu Z., Wang Y., Chen L., Zuo G.W., Pan X., Shen J., Vokes T., Reid R.R., Haydon R.C., Luu H.H., He T.C. A comprehensive analysis of the dual roles of BMPs in regulating adipogenic and osteogenic differentiation of mesenchymal progenitor cells. Stem Cells Dev. 2009, 18:545-559.
16. Katagiri T., Yamaguchi A., Komaki M., Abe E., Takahashi N., Ikeda T., Rosen V., Wozney J.M., Fujisawa-Sehara A., Suda T. Bone morphogenetic protein-2 converts the differentiation pathway of C2C12 myoblasts into the osteoblast lineage. J. Cell Biol. 1994, 127:1755-1766.
17. Kudo O., Fujikawa Y., Itonaga I., Sabokbar A., Torisu T., Athanasou N.A. Proinflammatory cytokine (TNFalpha/IL-1alpha) induction of human osteoclast formation. J. Pathol. 2002, 198:220-227.
18. Lecka-Czernik B. PPARs in bone: the role in bone cell differentiation and regulation of energy metabolism. Curr. Osteoporos. Rep. 2010, 8:84-90.
19. Lieberman J.R., Daluiski A., Einhorn T.A. The role of growth factors in the repair of bone. Biology and clinical applications. J. Bone Joint Surg. Am. 2002, 1032-1044.
20. Matsumoto Y., Otsuka F., Takano M., Mukai T., Yamanaka R., Takeda M., Miyoshi T., Inagaki K., Sada K.E., Makino H. Estrogen and glucocorticoid regulate osteoblast differentiation through the interaction of bone morphogenetic protein-2 and tumor necrosis factor-alpha in C2C12 cells. Mol. Cell. Endocrinol. 2010, 325:118-127.
21. Mbalaviele G., Abu-Amer Y., Meng A., Jaiswal R., Beck S., Pittenger M.F., Thiede M.A., Marshak D.R. Activation of peroxisome proliferator-activated receptor-gamma pathway inhibits osteoclast differentiation. J. Biol. Chem. 2000, 275:14388-14393.
22. McCarthy T.L., Centrella M., Canalis E. Regulatory effects of insulin-like growth factors I and II on bone collagen synthesis in rat calvarial cultures. Endocrinology 1989, 124:301-309.
23. Midy V., Plouet J. Vasculotropin/vascular endothelial growth factor induces differentiation in cultured osteoblasts. Biochem. Biophys. Res. Commun. 1994, 199:380-386.
24. Mukai T., Otsuka F., Otani H., Yamashita M., Takasugi K., Inagaki K., Yamamura M., Makino H. TNF-alpha inhibits BMP-induced osteoblast differentiation through activating SAPK/JNK signaling. Biochem. Biophys. Res. Commun. 2007, 356:1004-1010.
25. Otani H., Otsuka F., Inagaki K., Takeda M., Miyoshi T., Suzuki J., Mukai T., Ogura T., Makino H. Antagonistic effects of bone morphogenetic protein-4 and -7 on renal mesangial cell proliferation induced by aldosterone through MAPK activation. Am. J. Physiol. Renal Physiol. 2007, 292:F1513-F1525.
26. Otsuka F. Multiple endocrine regulation by bone morphogenetic protein system. Endocr. J. 2010, 57:3-14.
27. Otsuka F., McTavish K., Shimasaki S. Integral role of GDF-9 and BMP-15 in ovarian function. Mol. Reprod. Dev. 2011, 78:9-21.
28. Reddi A.H. Bone morphogenetic proteins: an unconventional approach to isolation of first mammalian morphogens. Cytokine Growth Factor Rev. 1997, 8:11-20.
29. Scott D.L., Kingsley G.H. Tumor necrosis factor inhibitors for rheumatoid arthritis. N. Engl. J. Med. 2006, 355:704-712.
30. Shimasaki S., Moore R.K., Otsuka F., Erickson G.F. The bone morphogenetic protein system in mammalian reproduction. Endocr. Rev. 2004, 25:72-101.
31. Spelsberg T.C., Subramaniam M., Riggs B.L., Khosla S. The actions and interactions of sex steroids and growth factors/cytokines on the skeleton. Mol. Endocrinol. 1999, 13:819-828.
32. Takeda M., Otsuka F., Otani H., Inagaki K., Miyoshi T., Suzuki J., Mimura Y., Ogura T., Makino H. Effects of peroxisome proliferator-activated receptor activation on gonadotropin transcription and cell mitosis induced by bone morphogenetic proteins in mouse gonadotrope LβT2 cells. J. Endocrinol. 2007, 194:87-99.
33. Willson T.M., Brown P.J., Sternbach D.D., Henke B.R. The PPARs: from orphan receptors to drug discovery. J. Med. Chem. 2000, 43:527-550.
34. Wu X., Peters J.M., Gonzalez F.J., Prasad H.S., Rohrer M.D., Gimble J.M. Frequency of stromal lineage colony forming units in bone marrow of peroxisome proliferator-activated receptor-alpha-null mice. Bone 2000, 26:21-26.
35. Yamashita M., Otsuka F., Mukai T., Otani H., Inagaki K., Miyoshi T., Goto J., Yamamura M., Makino H. Simvastatin antagonizes tumor necrosis factor-alpha inhibition of bone morphogenetic proteins-2-induced osteoblast differentiation by regulating Smad signaling and Ras/Rho-mitogen-activated protein kinase pathway. J. Endocrinol. 2008, 196:601-613.